Top

Published in:

01-02-2013 | Epidemiology

Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study

Authors: Adam J. Olszewski, Yazan Migdady, Susan K. Boolbol, Paula Klein, Kwadwo Boachie-Adjei, Bachir J. Sakr, William Sikov, Theresa Shao

Published in: Breast Cancer Research and Treatment | Issue 1/2013

Abstract

Previous studies have reported higher recurrence rates in T1a/b N0 breast cancers characterized by high-risk biology (HER2+ or triple-negative), but the benefits of adjuvant chemotherapy in these patients have not been established. This study was designed to determine whether recurrence risk is reduced with chemotherapy and to define a group of patients most appropriate for treatment based on retrospective data. We pooled cases from two multi-institutional databases spanning the period of 1996–2010. A propensity score model adjusted unbalanced confounders between the groups treated or untreated with adjuvant chemotherapy and, in case of HER2-positive disease, with trastuzumab. Competing risk analysis was utilized to study effects of chemotherapy on cancer recurrences in the matched populations. Among the 318 patients identified, 41 % received adjuvant chemotherapy and 54 % of HER2+ patients received it with trastuzumab. The cumulative risk of recurrence at 5 years was 7.3 %. Age less than 35 years and triple-negative status were the only significant prognostic factors. Overall, administration of chemotherapy was not associated with a significant decrease in the risk of recurrence (HR 0.93, p = 0.91). The rate of recurrence in HER2+ patients who received trastuzumab was lower but not statistically significant (HR 0.50, p = 0.63). Clinical characteristics are of limited prognostic value for stratifying risk of recurrence in very small, node-negative HER2+, or triple-negative cancers. While limited by the small number of events, our analysis does not support the increasingly prevalent practice of administering adjuvant chemotherapy in this population without more accurate prognostic and predictive factors.

Available only for authorised users

Curtis C, Shah SP, Chin SF et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. doi:10.1038/nature10983

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736–1747. doi:10.1093/annonc/mdr304 PubMedCrossRef

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684–1691. doi:10.1200/JCO.2009.24.9284 PubMedCrossRef

Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Cancer, Leukemia Group BI (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496–1506. doi:10.1056/NEJMoa071167 CrossRef

Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G, Goldhirsch A (2008) Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 19:465–472. doi:10.1093/annonc/mdm509 PubMedCrossRef

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant Trial Study T (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672. doi:10.1056/NEJMoa052306 CrossRef

Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684. doi:10.1056/NEJMoa052122 PubMedCrossRef

Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN (2006) Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a, bN0M0): a review of the literature. J Clin Oncol 24:2113–2122. doi:10.1200/JCO.2005.02.8035 PubMedCrossRef

Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, Wolmark N (2001) Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 93:112–120PubMedCrossRef

10.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M (2011) Prognosis in women with small (T1mic, T1a, T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 127:713–720. doi:10.1007/s10549-011-1465-7 PubMedCrossRef

11.

Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700–5706. doi:10.1200/JCO.2009.23.2025 PubMedCrossRef

12.

Ho AY, Gupta G, King TA, Perez CA, Patil SM, Rogers KH, Wen YH, Brogi E, Morrow M, Hudis CA, Traina T, McCormick B, Powell SN, Robson ME (2012) Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer 118:4944–4952. doi:10.1002/cncr.27480 PubMedCrossRef

13.

Kwon JH, Kim YJ, Lee KW, Oh DY, Park SY, Kim JH, Chie EK, Kim SW, Im SA, Kim IA, Kim TY, Park IA, Noh DY, Bang YJ, Ha SW (2010) Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. BMC Cancer 10:557. doi:10.1186/1471-2407-10-557 PubMedCrossRef

14.

Rodrigues MJ, Wassermann J, Albiges L, Brain E, Delaloge S, Stevens D, Guinebretiere JM, Mathieu MC, Kirova Y, Guillot E, Vincent-Salomon A, Cottu PH (2010) Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas. J Clin Oncol 28:e541–e542. doi:10.1200/JCO.2010.29.7952 PubMedCrossRef

15.

Shao T, Boolbol SK, Boachie-Adjei K, P K (2011) Clinical Significance of HER2+ and Triple-Negative Status in Patients with Tumor Size ≤ 1 cm and Node Negative Breast Cancer. Cancer Research February 24, 2012 71:P4-09-03. doi:10.1158/0008-5472.SABCS11-P4-09-03

16.

Migdady Y, Sikov WM, Sakr BJ, Olszewski AJ (2012) Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER2-positive breast cancer. J Clin Oncol 30, No 15_suppl: abstract 1034

17.

Hammond ME, Hayes DF, Dowsett M et al (2010) American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795. doi:10.1200/JCO.2009.25.6529 PubMedCrossRef

18.

Wolff AC, Hammond ME, Schwartz JN et al (2007) American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145. doi:10.1200/JCO.2006.09.2775 PubMedCrossRef

19.

Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127–2132. doi:10.1200/JCO.2006.10.3523 PubMedCrossRef

20.

Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46:399–424. doi:10.1080/00273171.2011.568786 CrossRef

21.

Biondi-Zoccai G, Romagnoli E, Agostoni P, Capodanno D, Castagno D, D’Ascenzo F, Sangiorgi G, Modena MG (2011) Are propensity scores really superior to standard multivariable analysis? Contemp Clin Trials 32:731–740. doi:10.1016/j.cct.2011.05.006 PubMedCrossRef

22.

Cepeda MS, Boston R, Farrar JT, Strom BL (2003) Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 158:280–287PubMedCrossRef

23.

Hernan MA, Brumback B, Robins JM (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11:561–570PubMedCrossRef

24.

Cole SR, Hernan MA (2008) Constructing inverse probability weights for marginal structural models. Am J Epidemiol 168:656–664. doi:10.1093/aje/kwn164 PubMedCrossRef

25.

Stuart EA (2010) Matching methods for causal inference: a review and a look forward. Stat Sci 25:1–21. doi:10.1214/09-STS313 PubMedCrossRef

26.

Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083–3107. doi:10.1002/sim.3697 PubMedCrossRef

27.

Sturmer T, Rothman KJ, Avorn J, Glynn RJ (2010) Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution–a simulation study. Am J Epidemiol 172:843–854. doi:10.1093/aje/kwq198 PubMedCrossRef

28.

Dignam JJ, Kocherginsky MN (2008) Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 26:4027–4034. doi:10.1200/JCO.2007.12.9866 PubMedCrossRef

29.

Mell LK, Jeong JH (2010) Pitfalls of using composite primary end points in the presence of competing risks. J Clin Oncol 28:4297–4299. doi:10.1200/JCO.2010.30.2802 PubMedCrossRef

30.

Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef

31.

Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L (2011) Coping with uncertainty: T1a, bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol 22:2387–2393. doi:10.1093/annonc/mdq786 PubMedCrossRef

32.

Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nole F, Goldhirsch A (2009) Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693–5699. doi:10.1200/JCO.2009.22.0962 PubMedCrossRef

33.

Lai HW, Kuo SJ, Chen LS, Chi CW, Chen ST, Chang TW, Chen DR (2011) Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller. Eur J Surg Oncol 37:18–24. doi:10.1016/j.ejso.2010.10.003 PubMedCrossRef

34.

Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB, Coppola KE, McLaughlin SA, Palmieri FM, Perez EA (2010) Prognosis and outcome of small (≤1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist 15:1043–1049. doi:10.1634/theoncologist.2010-0036 PubMedCrossRef

35.

Kaplan HG, Malmgren JA, Atwood M (2009) T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J 15:454–460. doi:10.1111/j.1524-4741.2009.00789.x PubMedCrossRef

36.

McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA (2011) Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 117:5461–5468. doi:10.1002/cncr.26171 PubMedCrossRef

37.

Rodrigues MJ, Peron J, Frenel JS, Vano YA, Wassermann J, Debled M, Picaud F, Albiges L, Vincent-Salomon A, Cottu PH (2012) Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. Ann Oncol. doi:10.1093/annonc/mds536

38.

Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N, National Surgical Adjuvant Breast and Bowel Project (2002) Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20:4141–4149. doi:10.1200/JCO.2002.11.101 PubMedCrossRef

39.

Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808–3815. doi:10.1200/JCO.2006.10.4976 PubMedCrossRef

40.

Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM (2011) Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 11:325–331. doi:10.1016/j.clbc.2011.05.002 PubMedCrossRef

41.

Han W, Kang SY (2010) Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 119:193–200. doi:10.1007/s10549-009-0388-z PubMedCrossRef

42.

Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S (2012) Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 18:1341–1351. doi:10.1158/1078-0432.CCR-11-2599 PubMedCrossRef

43.

Fehrenbacher L, Shiraz P, Sattavat M, Capra A, Quesenberry C, Fulton R, Habel LA (2011) T1abN0M0 HER2+ invasive breast cancer recurrence: Population-based cohort of 17,000+ consecutive breast cancers 2000-2006 at Kaiser Permanente Northern California (KPNC). J Clin Oncol 29, No 15_suppl: abstract 551

44.

Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10:R67. doi:10.1186/bcr2128 PubMedCrossRef

45.

Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Ferno M, Malmstrom PO, Johannsson OT, Loman N, Barkardottir RB, Borg A (2010) Identification of subtypes in human epidermal growth factor receptor 2–positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 28:1813–1820. doi:10.1200/JCO.2009.22.8775 PubMedCrossRef

46.

Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B (2012) Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 104:159–162. doi:10.1093/jnci/djr490 PubMedCrossRef

47.

Tsutsumi Y (2012) Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Jpn J Clin Oncol 42:375–386. doi:10.1093/jjco/hys034 PubMedCrossRef

48.

Perou CM (2010) Molecular stratification of triple-negative breast cancers. Oncologist 15(Suppl 5):39–48. doi:10.1634/theoncologist.2010-S5-39 PubMedCrossRef

49.

Carlson RW, Allred DC, Anderson BO et al (2011) Invasive breast cancer. J Natl Compr Canc Netw 9:136–222PubMed

Title: Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study
Authors: Adam J. Olszewski
Yazan Migdady
Susan K. Boolbol
Paula Klein
Kwadwo Boachie-Adjei
Bachir J. Sakr
William Sikov
Theresa Shao
Publication date: 01-02-2013
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2013
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-013-2423-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment

Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)

Racial differences in outcomes of triple-negative breast cancer

Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes

Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: a retrospective database analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer